Equities

Cantargia AB

Cantargia AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)3.14
  • Today's Change-0.662 / -17.41%
  • Shares traded697.15k
  • 1 Year change-28.28%
  • Beta1.5601
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-227.96m
  • Incorporated2009
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Curasight A/S-43.29m-48.36m337.53m4.00--17.48-----1.51-1.51-1.350.6008-0.7563-----7,107,500.00-84.49-24.61-111.31-26.01-----------32.260.4439---123.97---42.62------
Alzinova AB300.00k-18.12m340.61m5.00--2.02--1,135.37-0.332-0.3320.00551.890.0025--0.475260,000.00-15.15-10.77-15.91-11.27-2,621.00---6,039.67-18,447.90---392.890.0076-------25.92--15.81--
Herantis Pharma Oyj0.00-6.95m342.29m10.00--14.7714.53---0.0146-0.01460.000.10120.00----0.00-13.93-80.46-27.32-104.37------------0.0145------103.00------
Medivir AB6.83m-105.92m367.91m10.00--2.09--53.84-1.45-1.450.08241.570.0311--1.12683,300.00-48.26-28.91-61.14-34.77-1,152.23-467.42-1,550.15-675.96----0.0543--73.16-20.39-0.6275---47.96--
Lytix Biopharma AS-97.07bn-97.07bn379.48m10.00--6.60----------1.19-----------56.91---65.83-------771.78----0.0482---63.8263.94-56.77------
Initiator Pharma A/S0.00-25.73m386.53m3.00--14.24-----0.4688-0.46880.000.5130.00----0.00-65.39-68.27-73.28-74.02------------0.00------27.95------
Bergenbio ASA505.74k-150.85m392.70m15.00--2.31--776.49-5.37-5.370.0184.480.0023--0.041120,840.00-67.73-66.15-85.55-78.74-----29,828.21-11,419.44----0.00---9.00-31.4336.98------
SynAct Pharma AB0.00-165.96m408.84m5.00--2.19-----4.75-4.750.004.530.00----0.00-61.52-125.17-67.60-151.70-----------231.850.0076-------117.54------
Mendus AB (publ)0.00-141.42m412.29m28.00--0.5904-----3.54-3.540.0013.870.00----0.00-21.08-18.84-23.01-20.21-------28,474.53----0.0318---100.00--26.78------
Guard Therapeutics Intrntnl AB (publ)0.00-78.82m427.32m6.00--4.50-----7.83-7.830.006.450.00-------70.61-69.56-86.38-78.62------------0.00-------0.4289------
Hamlet BioPharma AB0.00-41.82m456.12m7.00---------0.2756-0.27560.00--------0.00---80.47---97.51---------------------104.57------
Oncopeptides AB21.37m-262.70m457.93m67.00--2.38--21.43-1.97-1.970.16040.91340.05280.0350.5727374,894.80-64.95-141.28-83.36-200.4999.44---1,229.37-2,689.063.44-49.510.4187--321.54--26.29------
Saniona AB24.88m-81.81m537.28m22.00--77.48--21.60-0.9821-0.98210.28220.06230.2386--6.231,081,652.00-78.47-59.16-168.78-70.15-92.01-970.05-328.83-1,483.55---3.030.8668--10.19-21.0554.71---34.94--
Cantargia AB0.00-227.96m576.78m23.00--6.37-----1.29-1.290.000.49320.00----0.00-98.38-55.08-129.99-61.35------------0.00------24.69------
Promimic AB40.92m-10.45m649.28m17.00--9.15--15.87-0.563-0.5632.213.800.4828-3.883.922,406,824.00-12.33-24.89-14.16-29.25104.60101.23-25.54-89.474.51--0.00--128.63--41.95------
Intellego Technologies AB231.25m82.86m658.82m62.008.253.057.282.853.033.038.508.200.82984.242.453,729,807.0029.74--37.90--68.61--35.83--1.888.840.1532--222.74--493.56------
Data as of Sep 20 2024. Currency figures normalised to Cantargia AB's reporting currency: Swedish Krona SEK

Institutional shareholders

28.87%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 202318.12m9.87%
F�rsta AP-fondenas of 31 Dec 202313.00m7.08%
Alecta Pension Insurance Mutualas of 30 Jun 202310.10m5.50%
Handelsbanken Fonder ABas of 31 Aug 20245.84m3.18%
Swedbank Robur Fonder ABas of 30 Aug 20243.69m2.01%
SEB Investment Management ABas of 30 Aug 20241.01m0.55%
FCG Fonder ABas of 30 Aug 2024626.22k0.34%
SSgA Funds Management, Inc.as of 05 Sep 2024365.04k0.20%
Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023160.18k0.09%
Skandia Investment Management ABas of 31 Jul 2024113.71k0.06%
More ▼
Data from 30 Jun 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.